Navigation Links
Mpex Candidate, MP-376, Granted U.S. Orphan Drug Status for the Treatment of Cystic Fibrosis
Date:3/4/2008

's marketing approval by the FDA. Orphan status also enables Mpex to apply for research funding, tax credits for certain research expenses, and a waiver from FDA user fees.

About MP-376

MP-376 is a proprietary formulation of levofloxacin that has been designed by Mpex scientists to enable aerosol administration. Levofloxacin is a powerful antibiotic that has been widely used in a variety of indications for over a decade and has established safety and efficacy when administered orally or intravenously against many bacterial pathogens including Pseudomonas aeruginosa. Administration of MP-376 with a high efficiency nebulizer to the lungs allows for the delivery of high concentrations of active drug directly to the site of infection, while minimizing systemic exposure. Mpex believes this approach has the potential to improve bacterial killing and reduce resistance development versus traditional oral or IV routes of administration.

Mpex recently completed a multi-center, 14-day placebo controlled clinical trial with MP-376 in 40 CF patients. Based on these results and consultations with the FDA and the Therapeutics Development Network (TDN) of the Cystic Fibrosis Foundation, the company expects to initiate a Phase 2b clinical trial in approximately 140 CF patients in the second quarter of 2008. Several dosing regimens of MP-376 will be compared, including once daily administration schedules. Results from this trial, if successful, are expected to enable the company to select dosing regimens for the pivotal Phase 3 clinical program in this indication.

About Mpex Pharmaceuticals

Mpex Pharmaceuticals is a clinical stage biopharmaceutical company whose mission is to develop important new therapies to combat the growing issue of antibiotic resistance. The company's internal development pipeline focuses on combining proprietary formulations, PK/PD strategies and novel potentiating agents with proven antibiotics to overcome or directly inhibi
'/>"/>

SOURCE Mpex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Odyssey Thera Granted U.S. Patent for Animal Imaging
2. ISTO Technologies Granted Key Patent for Cartilage Cell Expansion by the United States Patent Office
3. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
4. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
5. Pharmions Oral Azacitidine Granted Fast Track Status for Myelodysplastic Syndromes
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. Raptor Pharmaceuticals Acquires Orphan Clinical Program
8. Sequella Lead Drug Compound SQ109 Receives Orphan Drug Status From the US FDA and Orphan Medicinal Product Designation From the European Medicines Agency for the Treatment of Tuberculosis
9. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
10. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
11. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... April 27, 2015  Edico Genome today announced ... from Harvard and Stanford Universities showed the DRAGEN™ ... sequence with 300x depth of coverage by tenfold, ... 60 hours with standard software. "Processing ... especially for individual research and clinical labs, in ...
(Date:4/27/2015)... PA (PRWEB) April 27, 2015 Deadly ... Therapeutics, the newest resident of the University City ... Street in Philadelphia. , With a $4.5 million ... Health in hand, Phelix Therapeutics is focused ... developing nutritional supplements. The company is developing first-in-class protease ...
(Date:4/27/2015)... , 27 avril 2015 ... spécialisée dans le développement d,une nouvelle ... les infections bactériennes polypharmacorésistantes potentiellement mortelles, ... données prouvant les promesses de son ... la lutte contre la résistance aux ...
(Date:4/27/2015)... LONDON , April 27, 2015 ... about this release, please scroll to bottom . ... following equities: Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX ... Synta Pharmaceuticals Corporation (NASDAQ: SNTA ), Spectrum ... Inc. (NASDAQ: MDVN ). Free research report ...
Breaking Biology Technology:Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 2Edico Genome, in Collaboration with Researchers from Harvard and Stanford Universities, Speeds Analysis of Whole Genome Sequence with 300x Depth of Coverage Tenfold 3New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 2Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 3Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 4Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, Synta Pharma, Spectrum Pharma, and Medivation 5
... of protein precipitation with the selectivity of ... and proteins from biological samples prior to ... a division of Sigma-Aldrich (Nasdaq: ... chromatography products for analysis and purification, announces ...
... Champions Biotechnology, Inc. (OTC Bulletin Board: ... preclinical platforms and tumor specific data to enhance the ... Champions Biotechnology UK Ltd. (CBUK), to expand its personalized ... Manager of the UK subsidiary, which will also have ...
... German . , Leipzig: Research and industry ... as their application in research, medical diagnosis and treatment, ... for use in environmental analysis because their characteristics enable ... as a key fits a lock. In a new ...
Cached Biology Technology:HybridSPE(TM)-Precipitation Technology Wins SelectScience.net 2009 Scientists' Choice Award for Best New Separations Product in 2008 2HybridSPE(TM)-Precipitation Technology Wins SelectScience.net 2009 Scientists' Choice Award for Best New Separations Product in 2008 3Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business 2Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business 3Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business 4Fitting pieces for biosensors 2Fitting pieces for biosensors 3Fitting pieces for biosensors 4
(Date:4/27/2015)... , Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market, ... to pre-order customers the first week of May, 2015 ... month of May. Gino Pereira ... milestone for the company as Wocket® enters the consumer ...
(Date:4/27/2015)... LAUDERDALE, Fla. , Apr. 27, 2015 ... of access control and security systems is pleased to ... the company as a consultant and member of its ... is widely known as a thought leader in ... Distance Learning Technology Group, and has published studies and ...
(Date:4/21/2015)... 2015 High crime rate, ... boosting access control systems market in Saudi ... recently published report by TechSci Research " Saudi Arabia Access ... control systems market in Saudi Arabia ... access control systems market in the Kingdom is growing ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 2Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 3Profile Solutions Names Medicinal Cannabis, Agriculture and Technology Expert Dr. Gerry Bedore to its Scientific Advisory Board 4Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
... the tale of your family line. It carries the genetic ... a Tel Aviv University researcher, it,s also possible to use ... Eran Halperin of TAU,s Blavatnik School of Computer Science and ... of researchers from University of California, Los Angeles, are giving ...
... flock together and according to a new analysis so ... heritage of avian feather lice indicates that their louse ancestors first ... and then "radiated" to different habitats on those birds to ... species. This finding surprised the researchers because wing lice from many ...
... injured themselves during leisurely deep-sea diving trips and not from ... identified bone deformities on the fossilized remains of Ichthyosarians ... 245 million years ago. The lesions were similar ... in body pressure, and suggest the reptiles suffered from a ...
Cached Biology News:A GPS in your DNA 2Bird louse study shows how evolution sometimes repeats itself 2'Dinosaur bends' caused by prolonged diving 2
... Human IgG Fd. ELISA Specificity: (4) ,human IgG subclass 1 ... 100% ,human IgG subclass 3 100% ,human IgG ... ... 0.04% ,human IgG Fab ...
...
...
...
Biology Products: